Sep 5, 2008 5:03 PM ET | Site Changes | Help
Results 1 - 10 of 19 : 1 2 Next
A Partnership of Habitual Dealmakers
Takeda and Alnylam join forces.
Glaxo buys into Regulus' microRNA research.
The pharmaceutical's latest patent-licensing deal isn't immediately lucrative.
Alnylam presents proof of concept, but where's the proof that it cures a disease?
Take cheap when you can get it.
The Time Bomb in Your Portfolio
There are no safe investments.
Slowing the Cash Burn Bloody Nose
Nastech cuts costs and spins off a pre-clinical RNAi venture.
Who says investing is zero-sum? Members of our CAPS community love sharing investing knowledge.
Don't Let Bad Math Ruin Your Retirement
A few miscalculations can wreck a lifetime of saving and investing.
RNAi Doesn't Kill Mice After All
Alnylam and Roche researchers discover a workaround for an RNAi problem.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK